KPTI
NASDAQ
$7.47
Karyopharm Therapeutics Inc (KPTI)
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $13.50 (+80.72%)
Market Cap
$215M
Free Cash Flow Yield
-27.51%
Beta (5Y)
0.80
Price Chart
Valuation
Market Cap$215M
P/S1.50
P/B12.05
Profitability
Total Revenue (TTM)$151M
Gross Profit (TTM)$20M
EBITDA-$84M
Profit Margin-63.9%
Operating Margin-76.3%
EPS-$14.69
Financial Health
Free Cash Flow Yield-27.51%
Growth & Risk
EPS 5Y CAGR-18.43%
Revenue 5Y CAGR+5.95%
FCF 5Y CAGR-18.88%
Beta (5Y)0.80
Sharpe Ratio1.06